M1 KLINIKEN AG (M12.DE) Stock Fundamental Analysis
FRA:M12 - Deutsche Boerse Ag - DE000A0STSQ8 - Common Stock - Currency: EUR
M12 gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 25 industry peers in the Health Care Providers & Services industry. M12 has an excellent financial health rating, but there are some minor concerns on its profitability. M12 is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes M12 very considerable for growth investing!
1. Profitability
1.1 Basic Checks
M12 had positive earnings in the past year.
In the past year M12 had a positive cash flow from operations.
M12 had positive earnings in each of the past 5 years.
M12 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
M12's Return On Assets of 8.27% is amongst the best of the industry. M12 outperforms 95.83% of its industry peers.
M12 has a Return On Equity of 12.29%. This is in the better half of the industry: M12 outperforms 70.83% of its industry peers.
M12's Return On Invested Capital of 10.98% is amongst the best of the industry. M12 outperforms 95.83% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for M12 is in line with the industry average of 5.68%.
The 3 year average ROIC (5.33%) for M12 is below the current ROIC(10.98%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 12.29% | ||
| ROIC | 10.98% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.05%
ROE(5y)8.67%
ROIC(3y)5.33%
ROIC(5y)5.06%
1.3 Margins
M12 has a better Profit Margin (5.03%) than 79.17% of its industry peers.
In the last couple of years the Profit Margin of M12 has declined.
M12 has a Operating Margin (6.87%) which is in line with its industry peers.
In the last couple of years the Operating Margin of M12 has declined.
The Gross Margin of M12 (17.41%) is worse than 66.67% of its industry peers.
In the last couple of years the Gross Margin of M12 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% |
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so M12 is still creating some value.
The number of shares outstanding for M12 has been increased compared to 1 year ago.
M12 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, M12 has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 5.55 indicates that M12 is not in any danger for bankruptcy at the moment.
M12 has a better Altman-Z score (5.55) than 100.00% of its industry peers.
M12 has a debt to FCF ratio of 0.60. This is a very positive value and a sign of high solvency as it would only need 0.60 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.60, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
M12 has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.05, M12 belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.6 | ||
| Altman-Z | 5.55 |
ROIC/WACC1.66
WACC6.62%
2.3 Liquidity
M12 has a Current Ratio of 1.76. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of M12 (1.76) is better than 91.67% of its industry peers.
M12 has a Quick Ratio of 1.10. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
M12's Quick ratio of 1.10 is amongst the best of the industry. M12 outperforms 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
M12 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 163.65%, which is quite impressive.
M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 5.87% yearly.
The Revenue has grown by 12.05% in the past year. This is quite good.
Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 37.14% on average per year.
EPS 1Y (TTM)163.65%
EPS 3Y12.52%
EPS 5Y5.87%
EPS Q2Q%189.73%
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
3.2 Future
M12 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.45% yearly.
Based on estimates for the next years, M12 will show a quite strong growth in Revenue. The Revenue will grow by 9.46% on average per year.
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue Next Year12.09%
Revenue Next 2Y9.61%
Revenue Next 3Y9.23%
Revenue Next 5Y9.46%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 17.59 indicates a rather expensive valuation of M12.
Compared to the rest of the industry, the Price/Earnings ratio of M12 indicates a somewhat cheap valuation: M12 is cheaper than 66.67% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 28.47. M12 is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 15.40 indicates a correct valuation of M12.
The rest of the industry has a similar Price/Forward Earnings ratio as M12.
M12's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.74.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.59 | ||
| Fwd PE | 15.4 |
4.2 Price Multiples
The rest of the industry has a similar Enterprise Value to EBITDA ratio as M12.
M12's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 8.38 | ||
| EV/EBITDA | 9.99 |
4.3 Compensation for Growth
M12's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
M12 has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as M12's earnings are expected to grow with 39.45% in the coming years.
PEG (NY)0.2
PEG (5Y)3
EPS Next 2Y47.84%
EPS Next 3Y39.45%
5. Dividend
5.1 Amount
M12 has a Yearly Dividend Yield of 3.33%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.89, M12 pays a better dividend. On top of this M12 pays more dividend than 91.67% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.28, M12 pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y47.84%
EPS Next 3Y39.45%
M1 KLINIKEN AG
FRA:M12 (2/4/2025, 7:00:00 PM)
14.95
-0.05 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners3.31%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap293.62M
Analysts85.71
Price Target28.05 (87.63%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.33% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)6.07%
EPS NY rev (3m)6.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.95%
Revenue NY rev (3m)0.95%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.59 | ||
| Fwd PE | 15.4 | ||
| P/S | 0.88 | ||
| P/FCF | 8.38 | ||
| P/OCF | 8.09 | ||
| P/B | 2.15 | ||
| P/tB | 6.04 | ||
| EV/EBITDA | 9.99 |
EPS(TTM)0.85
EY5.69%
EPS(NY)0.97
Fwd EY6.49%
FCF(TTM)1.78
FCFY11.93%
OCF(TTM)1.85
OCFY12.35%
SpS16.97
BVpS6.94
TBVpS2.47
PEG (NY)0.2
PEG (5Y)3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.27% | ||
| ROE | 12.29% | ||
| ROCE | 15.68% | ||
| ROIC | 10.98% | ||
| ROICexc | 12.98% | ||
| ROICexgc | 44.89% | ||
| OM | 6.87% | ||
| PM (TTM) | 5.03% | ||
| GM | 17.41% | ||
| FCFM | 10.51% |
ROA(3y)3.84%
ROA(5y)5.12%
ROE(3y)7.05%
ROE(5y)8.67%
ROIC(3y)5.33%
ROIC(5y)5.06%
ROICexc(3y)7.46%
ROICexc(5y)7.66%
ROICexgc(3y)20.1%
ROICexgc(5y)16.58%
ROCE(3y)7.61%
ROCE(5y)7.23%
ROICexcg growth 3Y47.1%
ROICexcg growth 5Y10.13%
ROICexc growth 3Y26.66%
ROICexc growth 5Y-7.94%
OM growth 3Y19.76%
OM growth 5Y-14.29%
PM growth 3Y-8.75%
PM growth 5Y-20.36%
GM growth 3Y-11.67%
GM growth 5Y-14.71%
F-Score8
Asset Turnover1.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.6 | ||
| Debt/EBITDA | 0.26 | ||
| Cap/Depr | 24.28% | ||
| Cap/Sales | 0.37% | ||
| Interest Coverage | 16.74 | ||
| Cash Conversion | 129.38% | ||
| Profit Quality | 209.01% | ||
| Current Ratio | 1.76 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 5.55 |
F-Score8
WACC6.62%
ROIC/WACC1.66
Cap/Depr(3y)24.3%
Cap/Depr(5y)28.94%
Cap/Sales(3y)0.45%
Cap/Sales(5y)0.8%
Profit Quality(3y)264.66%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)163.65%
EPS 3Y12.52%
EPS 5Y5.87%
EPS Q2Q%189.73%
EPS Next Y89.39%
EPS Next 2Y47.84%
EPS Next 3Y39.45%
EPS Next 5YN/A
Revenue 1Y (TTM)12.05%
Revenue growth 3Y25.61%
Revenue growth 5Y37.14%
Sales Q2Q%11.24%
Revenue Next Year12.09%
Revenue Next 2Y9.61%
Revenue Next 3Y9.23%
Revenue Next 5Y9.46%
EBIT growth 1Y86.59%
EBIT growth 3Y50.43%
EBIT growth 5Y17.54%
EBIT Next Year101.33%
EBIT Next 3Y43.63%
EBIT Next 5YN/A
FCF growth 1Y68.01%
FCF growth 3Y71.63%
FCF growth 5Y106.12%
OCF growth 1Y62.27%
OCF growth 3Y57.15%
OCF growth 5Y48.73%